Pyxis Oncology (NASDAQ:PYXS) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Pyxis Oncology (NASDAQ:PYXS) from a hold rating to a sell rating in a research note released on Saturday.

PYXS has been the topic of several other research reports. Wedbush initiated coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Tuesday, March 24th. Finally, Stifel Nicolaus cut their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.83.

Pyxis Oncology Price Performance

PYXS opened at $2.28 on Friday. The company’s 50-day moving average is $1.72 and its 200 day moving average is $2.30. Pyxis Oncology has a fifty-two week low of $0.97 and a fifty-two week high of $5.55. The firm has a market capitalization of $143.30 million, a P/E ratio of -1.74 and a beta of 1.43.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). On average, equities research analysts expect that Pyxis Oncology will post -1.23 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the company. Laurion Capital Management LP grew its holdings in Pyxis Oncology by 32.3% during the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after purchasing an additional 1,170,505 shares during the period. Vanguard Group Inc. grew its holdings in Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after purchasing an additional 14,566 shares during the period. 683 Capital Management LLC grew its holdings in Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after purchasing an additional 366,910 shares during the period. Renaissance Technologies LLC grew its holdings in Pyxis Oncology by 22.0% during the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after purchasing an additional 160,300 shares during the period. Finally, Jane Street Group LLC grew its holdings in Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock valued at $904,000 after purchasing an additional 482,310 shares during the period. 39.07% of the stock is owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.